Vytrus Biotech Reports Its Best Quarter: Record Revenue and Rising EBITDA

On November 7th at 4:00 p.m., Estrategias de Inversión will broadcast live, through its YouTube channel, the presentation of Vytrus Biotech’s third quarter 2024 results. This exclusive event will feature the participation of Albert Jané, CEO, COO and co-founder of the company; Òscar Expósito, CEO, CSO and co-founder; and Jordi Rovira, CFO, who will analyze the company’s financial results and latest achievements.

Vytrus Biotech, a specialist in plant biotechnology active ingredients for the cosmetics sector, has achieved a new revenue record of €4.6 million over the last twelve months. This performance stands out in the context of the third quarter, where sales reached €1.19 million, representing an increase of 36% compared to the same quarter in 2023.

In the first nine months of the year, Vytrus managed to increase its turnover by 31% compared to the same period of the previous year, reaching €3.7 million. In addition, the company improved its EBITDA by 35%, placing it at €1.45 million, already exceeding the €1.29 million obtained during the whole of 2023.

Vytrus’ financial strength is complemented by growth in all of its geographic areas of operation

The United States and Europe stand out, with sales increasing by 27% , and Latin America, which showed growth of 106%, driven by Brazil, Mexico and Colombia. In Asia-Pacific, the increase was 21% , reflecting the global expansion of Vytrus, which has already sold its products in 39 countries.

This live event will allow investors and analysts to gain detailed insight into Vytrus’ recent achievements, including the launch of innovative products such as BAOLIFT™, which has gained international recognition at cosmetics industry trade shows, and future growth projections, with the goal of tripling revenue and quadrupling EBITDA by 2027.

__

(Featured image by Stock Birken via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in Ei Estrategias de Inversion. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us